Mode
Text Size
Log in / Sign up

Beta-blocker therapy shows variable outcomes for myocardial infarction patients based on ejection fractionBeta-blockers show mixed results for patients with heart conditions

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that beta-blocker benefits may vary depending on the patient's left ventricular ejection fraction status.

The meta-analysis evaluated the efficacy of oral beta-blocker therapy compared to no beta-blocker therapy in patients who recently experienced myocardial infarction. The study specifically looked at outcomes for those with both mildly reduced and preserved left ventricular ejection fractions, focusing on a composite endpoint of death, re-infarction, and heart failure.

Findings indicated that oral beta-blockers did not significantly reduce the primary composite outcome in patients with preserved left ventricular ejection fraction. However, the analysis identified a reduction in risk for those with mildly reduced left ventricular ejection fraction. The authors noted that individual components of the primary outcome, such as all-cause death or heart failure, did not show significant differences when pooled across the entire population.

Clinical interpretation should be cautious as the benefit observed in the mildly reduced group was identified through subgroup analysis. While beta-blockers remain a standard for those with reduced ejection fraction, their specific impact on patients with preserved or mildly reduced function requires careful clinical consideration based on individual patient profiles.

Living with a heart condition like heart failure or having survived a recent heart attack is a major life change. For many patients, the goal of daily medication is simple: stay safe and keep the heart pumping strongly. One common class of drugs used for this purpose is beta-blockers. These medications are often prescribed to protect the heart muscle after it has been damaged by a heart attack. However, doctors are still looking closely at exactly who these drugs help the most and how well they work across different types of heart function.

To get a clearer picture, researchers looked at data from over 19,000 patients. This large group included people who had recently suffered a heart attack and had different levels of heart pumping strength. Specifically, they looked at those with mildly reduced pumping power and those whose hearts were still pumping at a normal or preserved level. The goal was to see if taking oral beta-blockers reduced the risk of serious events like death, having another heart attack, or developing heart failure over a period of 12 months.

The results showed a nuanced picture. For patients with mildly reduced heart pumping strength, the study found that beta-blocker therapy did reduce the risk of major complications. This aligns with what doctors have seen in many other cases where the heart muscle is weakened. However, for patients whose hearts were still pumping at a normal or preserved level, the data showed no significant difference between those taking the medication and those who did not. It is important to remember that this study was a meta-analysis, which means it combined results from several different trials to find a broader trend. While the findings for the mildly reduced group are encouraging, the lack of clear benefit in the preserved group suggests that heart function levels might change how these drugs work. It is also worth noting that the study did not show specific differences based on sex, and it did not find individual improvements in all-cause death or re-infarction when looking at the whole group together.

For patients right now, this means that while beta-blockers remain a standard tool for heart health, their impact can vary depending on your specific heart function. You should not change any medications based on this report alone. Instead, these findings provide helpful information for you and your doctor to discuss during your next checkup. Your medical team can use these details to better tailor your treatment plan based on your unique heart health profile.

What this means for you:
Beta-blockers show a clear benefit for some heart patients but may not show the same results for all.

Study Details

Study typeMeta analysis
Sample sizen = 19,826
EvidenceLevel 1
Follow-up12.0 mo
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: In the contemporary reperfusion era, the benefit of beta-blocker therapy in patients after acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) remains unclear. Recently conducted clinical trials have demonstrated mixed results about the clinical benefit of beta-blockers after myocardial infarction in pooled populations of patients with mildly reduced (LVEF 40-49%) or preserved LVEF. However, new evidence suggests a consistent benefit of beta-blocker therapy in patients specifically with mildly reduced LVEF. We aimed to assess the efficacy of beta-blockers in patients with recent myocardial infarction and mildly reduced or preserved LVEF, as well as specifically with preserved LVEF. METHODS: We conducted a systematic review of recent randomized controlled trials that evaluated the effects of oral beta-blocker therapy in patients with AMI who had either mildly reduced LVEF or preserved LVEF and with follow-up data of at least 1 year. Using a Mantel-Haenszel random effects model, we computed risk ratios (RR) with 95% confidence intervals for the primary composite outcome along with individual outcomes of death, re-infarction, and heart failure between patients with and without beta-blocker therapy. We performed analysis of the pooled overall study population, which included patients with mildly reduced LVEF and preserved LVEF, as well as performed subgroup analysis of patients with preserved versus mildly reduced LVEF and among men versus women. RESULTS: 19,826 patients with mildly reduced or preserved LVEF were included in the meta-analysis. Overall, 9,892 patients were assigned to beta-blockers and 9,934 to no beta-blockers. Among the pooled population, we did not demonstrate significant differences between the beta-blocker group and the control group for the primary composite outcome (RR 0.93, 95% CI 0.83-1.04), all-cause death, reinfarction, or heart failure. We further did not detect differences in the primary outcome by sex. While there was no differences in the primary composite outcome among patients with preserved LVEF (RR 0.96, 95% CI 0.86-1.08), there was reduction in risk observed among individuals with mildly reduced LVEF (RR 0.76, 95% CI 0.61-0.94). CONCLUSION: Oral beta-blocker therapy was not associated with a reduction in the primary composite outcome in patients with preserved LVEF. This contrasts with their established benefit in patients with reduced LVEF and the growing evidence of benefit in those with mildly reduced LVEF.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.